🟢 MEDPAL AI is trading 11.36% up today after FDA approval broadens Mounjaro’s cardiovascular use

MEDPAL AI is trading 11.36% up at £4.90 after highlighting the FDA’s September 1, 2026 approval expanding Mounjaro’s use to reduce major cardiovascular events in certain adults with type 2 diabetes.

• The announcement points to a larger GLP-1 opportunity and potential relevance to MEDPAL AI’s existing Mounjaro distribution arrangements.
• The move was company-specific rather than driven by broad market conditions, with shares rising sharply during the September 2 session.
• The RNS was issued September 1 and updated September 2.